Information for Patients and Physicians

Non-Hodgkin lymphoma represents a diverse group of cancers that develop in the lymphatic system and are characterized by uncontrolled growth and accumulation of abnormal lymphocytes. Lymphocytes are a type of white blood cell that are responsible for defending the body against infection. The most common forms of non-Hodgkin lymphoma are follicular (slower growing subtype) and diffuse large B-cell lymphoma (faster growing subtype). According to the American Cancer Society, more than 66,000 people will be diagnosed with non-Hodgkin lymphoma in the United States during 2011.

NON-HODGKIN LYMPHOMA TRIALS CURRENTLY ENROLLING
Brentuximab vedotin phase II trial for for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas

Evaluating the activity and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, peripheral T-cell lymphoma and other less common lymphoma subtypes.

See study details ›

Brentuximab vedotin phase II trial for retreatment of patients who previously participated in a brentuximab vedotin study

Evaluating the potential for retreatment with brentuximab vedotin in patients who have relapsed after discontinuing previous brentuximab vedotin therapy

See study details ›

Brentuximab vedotin phase I trial for front-line treatment of CD30-positive mature T-cell malignancies

Evaluating safety of brentuximab vedotin when administered sequentially and combined with multi-agent chemotherapy in  newly diagnosed patients with CD30-positive mature T-cell malignancies

See study details ›

SGN-75 phase I trial for CD70-positive non-Hodgkin lymphoma

Single-agent dose-escalation trial assessing the safety, tolerability, pharmacokinetics and antitumor activity of SGN-75 in patients with relapsed or refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma; enrollment to this trial is complete

See study details ›

NON-HODGKIN LYMPHOMA PATIENT RESOURCES

If you have questions about the non-Hodgkin lymphoma clinical trials, please e-mail Seattle Genetics at clinicaltrials@seagen.com. Additional information about cancer, lymphoma and participating in clinical trials can be found on the following web sites.

Privacy Policy  |  Legal Notice